贝那普利治疗非增生期糖尿病视网膜病变的临床研究

目的：评价贝那普利对非增生期糖尿病视网膜病变的治疗作用。方法选取确诊为2型糖尿病合并早期糖尿病肾病并发非增生期糖尿病性视网膜病变患者29例，按随机数字表法分为贝那普利治疗组（12例）和常规治疗对照组（17例），于服药前、后3个月及6个月行收缩压、舒张压、空腹血糖、糖化血红蛋白、血肌酐、尿微量白蛋白、最佳矫正视力及眼底血管荧光造影检查，并对结果进行统计分析。结果贝那普利治疗组服药3个月后空腹血糖、糖化血红蛋白、血肌酐、尿微量白蛋白与服药前及常规治疗组差异无统计学意义（ P ＞0.05），收缩压、舒张压较服药前降低，但差异无统计学意义（ P ＞0.05）；贝那普利治疗组服药6个月后收缩压、舒张压、空腹血糖、糖化血红蛋白、血肌酐、尿微量白蛋白与服药前及常规治疗组比较差异均有统计学意义（ P ＜0.05）。根据最佳矫正视力及眼底血管荧光造影结果，发现经贝那普利治疗后的患者糖尿病性视网膜病变进展缓慢，与对照组同期比较差异有统计学意义（ P ＜0.05）。结论血管紧张素转换酶抑制剂贝那普利对非增生期糖尿病性视网膜病变具有一定的保护作用，从而延缓非增生期糖尿病性视网膜病变的进展，减少严重并发症发生。

Clinical study of therapeutic effect of benazepril on nonproliferative diabetic retinopathy

Ojectvie To investigate therapeutic effect of benazepril on nonproliferative diabetic retinopathy （ NPDR） .Meth-ods Twenty nine patients with early diabetic nephropathy complicated with type 2 diabetes and NPDR were randomly divided into benazepril group （ n =12） and conventional therapy control group （ n =17）.The changes of blood pressure , blood glucose, glycosy-lated hemoglobin , blood creatinine , urinary albumin , best corrected visual acuity （ BCVA ） , and fluorescein fundus angiography （ FFA） were observed before and after 3 and 6 months of treatment .Results After 3 months of treatment by benazepril , all laboratory detection parameters were no significant difference compared with before treatment and conventional therapy control group （ P ＆gt;0.05）;While after 6 months, compared with before treatment and control group , blood pressure, blood glucose, glycosylated hemoglo-bin, blood creatinine , and urinary albumin were significantly decreased （ P ＆lt;0.05 ）; According to the results of BCVA and FFA , progression of pathological changes of NPDR were significantly slower in benazepril group compared with control group （ P ＆lt;0.05 ） . Conclusions Benazepril has some protection effect for NPDR to delay NPDR development and decrease serious complications .